T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …

Administration of bispecific antibodies (biAbs) in tumor therapy is limited by their short half-
life and off-target toxicity. Optimized strategies or targets are needed to overcome these …

Therapeutic approaches are needed to promote T cell–mediated destruction of poorly
immunogenic,“cold” tumors typically associated with minimal response to immune …

Abstract Vγ9Vδ2 T cells are effector cells with proven antitumor efficacy against a broad
range of cancers. This study aimed to assess the antitumor activity and safety of a bispecific …

CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory
hematological malignancies, but responses in solid tumors have been limited so far. One of …

Simple Summary Research into the immunotherapeutic potential of T cells has
predominantly focused on conventional alpha beta (αβ) T cells, which recognize peptide …

T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs),
has shown promising clinical outcomes in many cancers; however, these therapies have …

T cell–engaging bispecific antibodies (TCB) are highly potent therapeutics that can recruit
and activate cytotoxic T cells to stimulate an antitumor immune response. However, the …

Simple Summary CD3 complex provides the first signal sensed by the TCR of the
lymphocyte to trigger its activation. Thus, it becomes a very attractive receptor to determine …